Beijing Biostar Pharmaceuticals: Four Utidelone Clinical Studies Selected for ASCO 2026
Key Points for Investors
- Four clinical study results of Biostar’s core products, Utidelone Injection (UTD1) and Utidelone Capsule (UTD2), have been selected for poster presentation at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
- The selected studies cover advanced breast cancer, platinum-resistant ovarian cancer, HER2-positive advanced breast cancer, and castration-resistant prostate cancer.
- Clinical data demonstrate promising efficacy and safety profiles for both investigational drugs, with notable improvements in patient convenience and tolerability.
- These developments signal potential for new indications and expanded clinical use, supporting Biostar’s pipeline and future commercial opportunities.
Detailed Clinical Trial Results
1. Phase II Study: Utidelone Capsule (UTD2) for Advanced Breast Cancer
– Conducted by Academician Xu Binghe (Cancer Hospital, Chinese Academy of Medical Sciences).
– Combination therapy: UTD2 + capecitabine (CAP) in metastatic breast cancer patients previously treated with taxanes or anthracyclines.
– Efficacy: Of 44 evaluable patients, 27 achieved partial response (PR) and 12 had stable disease (SD). Objective response rate (ORR): 52.3%, Disease control rate (DCR): 88.6%. Median progression-free survival (mPFS): 8.25 months; median duration of response: 7.62 months.
– Safety: Peripheral neurotoxicity (grade ≥3) reduced from 25.1% (UTD1+CAP historical data) to 2% (UTD2+CAP). Grade 3/4 hematological toxicity extremely low.
– Significance: UTD2 offers superior convenience and tolerability, supporting its suitability for long-term use and providing a new oral therapeutic option for advanced breast cancer.
2. Phase II Study: Utidelone Capsule (UTD2) + Fruquintinib for Platinum-Resistant Ovarian Cancer (FRUTD Trial)
– Corresponding author: Wu Xiaohua (Fudan University Shanghai Cancer Center).
– Open-label, Simon’s two-stage phase II study.
– Efficacy: 19 patients enrolled, 14 evaluable. 9 achieved PR, 5 had SD. ORR: 64.3%, DCR: 100%. Median PFS: 7 months. Median overall survival not yet reached.
– Safety: Most adverse events were grade 1-2. No grade 4 or above TRAEs.
– Significance: Demonstrated encouraging efficacy and manageable safety in platinum-resistant recurrent ovarian cancer. Study ongoing; final data pending.
3. Phase II Study: Utidelone Injection (UTD1) with Inetetamab and Pyrotinib for HER2-Positive Advanced Breast Cancer
– Corresponding author: Sun Tao (Liaoning Cancer Hospital).
– Evaluated as first- or second-line treatment.
– Efficacy: 85 patients evaluable. 6 CR, 64 PR, 7 SD. ORR: 82.4%, mPFS: 13.1 months. OS rates: 94.6% at 12 months, 85.2% at 26 months, 78.5% at 35 months.
– Safety: Most common grade ≥3 TRAEs: diarrhea (28.2%), peripheral neurotoxicity (4.7%). Both manageable.
– Significance: Outstanding efficacy and favorable safety profile for HER2-positive advanced breast cancer in first- and second-line settings.
4. Phase II Study: Utidelone Injection (UTD1) for Castration-Resistant Prostate Cancer
– Corresponding author: Shi Yanxia (Sun Yat-sen University Cancer Center).
– Single-arm trial in mCRPC patients previously treated with docetaxel and hormonal therapy.
– Efficacy: 43 patients enrolled. PSA50 response rate: 23.3%, PSA30: 32.6%. Radiographic PFS: 6.7 months, median OS: 11.4 months. ORR: 17.4%, DCR: 56.5%.
– Safety: Most TEAEs were grade 1/2 and manageable. Grade 3/4 TEAEs included anemia, peripheral sensory neuropathy, vomiting, and diarrhea.
– Significance: Encouraging activity and manageable safety in heavily pretreated mCRPC patients.
Potential Price-Sensitive Implications
- The selection of four clinical studies for presentation at ASCO 2026 signals significant scientific recognition of Biostar’s pipeline and clinical progress.
- Positive efficacy and safety data across multiple indications could accelerate regulatory and commercial pathways for Utidelone products, potentially enhancing market value.
- The successful development and commercialization of these products could materially impact Biostar’s financial performance and share price.
- Warning: There is no guarantee that Utidelone or its combination therapies will be successfully developed or commercialized. Investors are advised to exercise caution.
Corporate Update
The Board comprises Dr. Tang Li (Chairman and Executive Director), Dr. Qiu Rongguo, Mr. Zhang Cheng, Dr. Guan Jin (executive Directors), Mr. Tang Jin, Ms. Dai Xuefen (non-executive Directors), and Mr. Shiu Shu Ming, Dr. Ye Chengang (independent non-executive Directors).
Disclaimer
The information above is provided for informational purposes only and does not constitute investment advice. Clinical development outcomes are subject to regulatory review and may not result in commercialization. Investors should exercise caution and consult professional advisors before making any investment decisions.
